Sign in

Catherine Szyman [March 26

Chief Executive Officer at MASIMO
Board
Since February 12, 2025
Age
58 years
Education
Holds a bachelor's degree in Accounting and International Business from the University of St. Thomas and an M.B.A. from Harvard Business School.
Tenure
Joined MASI in February 2025 as Chief Executive Officer and Director.

Also at MASIMO

BM[2
Bilal Muhsin [March 26
Chief Operating Officer
BT[2
Blair Tripodi [March 26
Chief Operating Officer, Consumer Division

About

Catherine Szyman is a seasoned executive serving as the Chief Executive Officer and Director at MASI. As of March 26, 2025, she is 58 years old.

She holds a bachelor's degree in Accounting and International Business from the University of St. Thomas and an M.B.A. from Harvard Business School, which laid the foundation for her extensive career in the healthcare and medical device industry.

Prior to joining MASI, she held key leadership roles at prominent companies such as Medtronic, Edwards Lifesciences, and Becton Dickinson and Company, where she was instrumental in driving innovation and revenue growth.

Her appointment as CEO at MASI on 02-12-2025 underscores her commitment to advancing patient-focused solutions and strategic growth initiatives, positioning the company for continued success in the evolving healthcare sector.

$MASI Performance Under Catherine Szyman [March 26

Past Roles

OrganizationRoleDate RangeDetails
Becton, Dickinson and Company (BD) Worldwide President, Advanced Patient Monitoring 2024 – February 2025 Acquired from Edwards Lifesciences; focused on AI-driven solutions
Edwards Lifesciences Corporation Corporate Vice President, General Manager, Critical Care 2015 – 2024 Accelerated revenue growth by introducing AI-driven solutions
Medtronic, Inc. Various leadership roles (including President, Medtronic Diabetes; Senior Vice President; Worldwide President of Endovascular and Diabetes Business Units) 1991 – 2015 Held roles in corporate strategy, business development, and finance
University of St. Thomas (Opus School of Business) Board Member N/A Served on the board of the academic institution

External Roles

OrganizationRoleDate RangeDetails
Inari Medical Board Member (including Compensation Committee) Active as of March 26, 2025 N/A
JSerra Catholic High School Board Member Active as of March 26, 2025 N/A

Fixed Compensation

Data from  FY 2025
Component NameAmountPayment ScheduleAdditional Details
Base Salary$1,000,000 AnnualFixed annual base salary
Severance - Termination Without Cause/With Good Reason$3,000,000 Equal installments over 18 monthsCalculated as 1.5×(Base Salary + Target Bonus); includes prorated annual bonus, COBRA benefit for up to 18 months, 90-day stock option exercisability, and vesting acceleration of Buy-Out RSUs and PSUs.
Severance - Termination Following Change in Control$6,000,000 Lump sumCalculated as 3×(Base Salary + Target Bonus); includes prorated target bonus, COBRA benefit, 90-day stock option exercisability, and full vesting acceleration of unvested equity awards.
Severance - Termination Due to Death or DisabilityN/A Dependent on termination dateIncludes prorated actual bonus, stock option exercisability, and vesting acceleration of Buy-Out RSUs.

Performance Compensation

Data from  FY 2025

Annual Bonus

MetricValueDetails
Base Salary$1,000,000 Base figure used for bonus calculations
Target Bonus100% of Base Salary (i.e., $1,000,000) Annual bonus opportunity based on performance; specific performance metrics are not provided
Maximum Bonus200% of Target (i.e., $2,000,000) Maximum potential bonus; performance thresholds not explicitly detailed

Annual Target Long-Term Incentive Award

MetricWeightThresholdTargetMaximum
Adjusted Revenue50% 95% achievement (50% payout) 100% achievement (100% payout) 105% achievement (200% payout)
Adjusted Non-GAAP EPS40% 90% achievement (50% payout) 100% achievement (100% payout) 110% achievement (200% payout)
Adjusted True Incremental Contract Value10% 90% achievement (50% payout) 100% achievement (100% payout) 110% achievement (200% payout)
  • Vesting Schedule: Performance Stock Units (60% of a $7,000,000 award) vest on a three-year cliff; Stock Options (20%) vest ratably over five years; Restricted Stock Units (20%) vest ratably over four years.
  • Grant Date: February 12, 2025.
  • Award Opportunity: $7,000,000.
  • Evaluation Period & Details: Payout percentages are determined based on achievement levels against each metric. Performance results directly influence the final award payout.

One-Time Buy-Out Award PSUs

MetricWeightThresholdTargetMaximum
Three-Year Cumulative Adjusted Revenue60% 93% achievement (50% payout) 100% achievement (100% payout) 107% achievement (200% payout)
Three-Year Cumulative Adjusted Non-GAAP Operating Income40% 90% achievement (50% payout) 100% achievement (100% payout) 110% achievement (200% payout)
  • Vesting Schedule: As per the company’s 2025 vesting terms for annual awards.
  • Grant Date: February 12, 2025.
  • Grant Date Fair Value: $4,000,000.
  • Additional Details: Incorporates a Relative TSR Modifier to align with shareholder returns; the grant date stock price is not provided.